Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference
February 15 2017 - 1:58PM
Editas Medicine, Inc. (NASDAQ:EDIT) announced today that the U.S.
Patent and Trademark Office (USPTO) issued a favorable decision in
the CRISPR interference between the University of California, the
University of Vienna, Emmanuelle Charpentier and the Broad
Institute, Inc. (Broad) regarding certain CRISPR-Cas9 patents the
Company exclusively licenses from Broad. The USPTO granted Broad’s
Motion for No Interference in Fact, ending the interference before
the USPTO.
“We are pleased with the USPTO’s decision of ‘no interference in
fact’ for the patents that have been granted to the Broad Institute
for their innovative and fundamental work on CRISPR-Cas9 genome
editing,” said Katrine Bosley, President and Chief Executive
Officer of Editas Medicine. “This important decision affirms the
inventiveness of the Broad’s work in translating the biology of the
natural world into fundamental building blocks to create
unprecedented medicines. At Editas Medicine, we are continuing to
invest in this technology to build our business for the long-term
and to create genome editing therapies for patients suffering from
genetically-defined and genetically-treatable diseases.”
About Editas MedicineEditas Medicine is a
leading genome editing company dedicated to treating patients with
genetically-defined diseases by correcting their disease-causing
genes. The Company was founded by world leaders in genome
editing, and its mission is to translate the promise of genome
editing science into a broad class of transformative genomic
medicines to benefit the greatest number of patients.
Forward-Looking StatementsThis press release
contains forward-looking statements and information within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "target," "should," "would," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. The
Company may not actually achieve the plans, intentions, or
expectations disclosed in these forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various factors,
including: uncertainties inherent in the initiation and completion
of preclinical studies and clinical trials and clinical development
of the Company's product candidates; availability and timing of
results from preclinical studies and clinical trials; whether
interim results from a clinical trial will be predictive of the
final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to
market products and availability of funding sufficient for the
Company's foreseeable and unforeseeable operating expenses and
capital expenditure requirements. These and other risks are
described in greater detail under the caption "Risk Factors"
included in the Company's most recent Quarterly Report on Form
10-Q, which is on file with the Securities and Exchange Commission,
and in other filings that the Company may make with the Securities
and Exchange Commission in the future. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and the Company expressly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Media Contact
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor Contact
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
mark.mullikin@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Sep 2023 to Sep 2024